Xencor Selects Antibody Development Candidates MONROVIA, Calif.—(BUSINESS WIRE)—Xencor, Inc., a leader in antibody optimization, has selected two humanized monoclonal antibody candidates, XmAb™ 5574 and XmAb™ 5483, for IND-enabling pre-clinical development for the treatment of B-cell malignancies

Xencor Data Published in Journal of Immunology Demonstrate Selectivity of New Class of Inhibitors for Inflammatory Disease MONROVIA, Calif.–(BUSINESS WIRE)–Jul 23, 2007 – A first-in-class protein therapeutic drug candidate has been shown to selectively inhibit its therapeutic target, according to

Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization Agreement Monrovia, CA – February 13, 2007. Xencor, Inc., a protein and antibody therapeutics development company, today announced a collaboration with Boehringer Ingelheim to optimize therapeutic monoclonal

Xencor Completes $45 Million Financing with MedImmune Ventures, Novo Nordisk and HealthCare Ventures Monrovia, CA – October 19, 2006 – Xencor, a company developing protein and antibody therapeutics, today announced that it raised $45 million in a private financing led by MedImmune Ventures, Inc.,

Xencor’s XmAb™ Technology Wins Wall Street Journal 2006 Technology Innovation Award MONROVIA, CA – September 11, 2006 – Xencor, Inc., a biotherapeutics company developing protein and antibody therapeutics, announced today that it has been named by The Wall Street Journal as a 2006 Wall Street

Xencor Completes $6 Million Bridge Financing with Novo Nordisk and Existing Investors Monrovia, CA – July 11, 2006 – Xencor, a biotherapeutics company developing protein and antibody therapeutics, today announced that it raised $6 million in a bridge financing from new investor Novo Nordisk and

Data Published in PNAS Show Engineering the Fc Region of Antibodies Makes Them More Toxic to Cancer Cells Monrovia, CA – March 7, 2006 – Engineering the “Fc“ region of monoclonal antibodies (mAbs) increases their toxicity to cancer cells, potentially improving the utility of targeted cancer

Xencor Licenses Immunofilter™ Technology to Centocor Research and Development, Inc. Monrovia, CA – February 14, 2006 – Xencor, Inc., a biotherapeutics company developing protein and antibody therapeutics, today announced that it has granted Centocor Research and Development, Inc.

Proprietary tool to assess potential protein immunogenicity for 95% of U.S. population.

Xencor and Roche Extend XmAb™ Antibody Therapeutics Collaboration Monrovia, CA – January 4, 2005 – Xencor, Inc., a biotherapeutics company developing protein and antibody therapeutics, today announced an extension to its research collaboration with Roche to create monoclonal antibodies with